- Home
- MLYS vs MREO Comparison
MLYS vs MREO Comparison
Compare MLYS & MREO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MLYS
- MREO
- Stock Information
- Founded
- MLYS 2019
- MREO 2015
- Country
- MLYS United States
- MREO United Kingdom
- Employees
- MLYS N/A
- MREO N/A
- Industry
- MLYS Biotechnology: Pharmaceutical Preparations
- MREO Biotechnology: Pharmaceutical Preparations
- Sector
- MLYS Health Care
- MREO Health Care
- Exchange
- MLYS Nasdaq
- MREO Nasdaq
- Market Cap
- MLYS 510.6M
- MREO 482.5M
- IPO Year
- MLYS 2023
- MREO N/A
- Fundamental
- Price
- MLYS $9.56
- MREO $2.85
- Analyst Decision
- MLYS Strong Buy
- MREO Strong Buy
- Analyst Count
- MLYS 2
- MREO 6
- Target Price
- MLYS $27.00
- MREO $7.83
- AVG Volume (30 Days)
- MLYS 280.6K
- MREO 917.3K
- Earning Date
- MLYS 02-12-2025
- MREO 03-26-2025
- Dividend Yield
- MLYS N/A
- MREO N/A
- EPS Growth
- MLYS N/A
- MREO N/A
- EPS
- MLYS N/A
- MREO N/A
- Revenue
- MLYS N/A
- MREO $1,000,000.00
- Revenue This Year
- MLYS N/A
- MREO N/A
- Revenue Next Year
- MLYS N/A
- MREO N/A
- P/E Ratio
- MLYS N/A
- MREO N/A
- Revenue Growth
- MLYS N/A
- MREO N/A
- 52 Week Low
- MLYS $8.58
- MREO $2.53
- 52 Week High
- MLYS $16.91
- MREO $5.02
- Technical
- Relative Strength Index (RSI)
- MLYS 42.42
- MREO 38.17
- Support Level
- MLYS $8.98
- MREO $2.82
- Resistance Level
- MLYS $10.75
- MREO $2.99
- Average True Range (ATR)
- MLYS 0.72
- MREO 0.13
- MACD
- MLYS 0.02
- MREO 0.01
- Stochastic Oscillator
- MLYS 27.49
- MREO 14.74
About MLYS Mineralys Therapeutics Inc.
Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking three or more antihypertensive medications typically including a diuretic.
About MREO Mereo BioPharma Group plc
Mereo BioPharma Group PLC is a United Kingdom (U.K.) based biopharmaceutical company focused on the development of innovative therapeutics for rare diseases. The Company has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat primarily for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD).